Cumulatively, this study demonstrates that anti-MUC16 chimeric mAb5E6 curtails MUC16-mediated EMT by targeting the FAK/p70S6K/N-cadherin signaling axis, thereby decreasing tumor progression and metastasis. Here, RPS6KB1 is linked to neoplasm.